Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis

Table 2

Characteristics of 124 TNBC patients assessed for BRCA1/2 mutations.

Factor	Patients tested for BRCA mutations				value (BRCA-positive vs BRCA-negative)
	BRCA noncarriers	Rate (%)	BRCA carriers	Rate (%)
Number of patients	94	100	30	100
Age at diagnosis (years)
Median	49		40		0.0115
Mean	47.5		41.4
Range	25–67		24–76
Clinical staging (cTNM)
I	23	24.5	14	47	0.0006
II	51	54	13	43
III	19	20	2	7
IV	1	<0.5	1	3
Initial clinical tumor staging
cT0	0	0	0	0	0.0004
cT1	28	30	16	53
cT2	56	59.5	9	30
cT3	4	4	2	7
cT4	6	6.5	3	10
No available data	0	0	0	0
Initial clinical node staging
cN0	55	58.5	19	63	0.1063
cN1	27	28.5	10	33
cN2	9	9.5	1	4
cN3	3	3.5	0	0
No available data	0	0	0	0
HER2 expression
0 or 1+	79	84	29	97	0.0091
2+, FISH negative	15	16	1	3
Histological type
NST	80		21	70	0.0023
Lobular	5	85	1	3.5
Medullar	5	5.5	1	3.5
Apocrine	2	5.5	1	3.5
Metaplastic	2	2	2	6
Others	0	2	4	13.5
G
1	0	0	2	6.5	0.0065
2	29	30	12	40
3	64	68	16	53.5
No available data	1	2	0	0
Ki-67 expression
<14%	26	27.5	5	16.5	0.0761
14–30%	29	31	10	33.5
>30%	28	30	13	43.5
No available data	11	11.5	2	6.5
Vimentin expression assessed
Yes	82	87	26	86.5	0.8361
No	12	13	4	13.5
Vimentin
Positive	14	15	8	26.5	0.0372
Negative	68	85	18	73.5
Contralateral breast cancer	13	14	8	26.5	0.0228
Other primary cancer (other than contralateral breast cancer)	9	9.5	5	16.5	0.1475

FISH: fluorescence in situ hybridization.